Skip to main content
Equibles

Rafael Amado

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Rafael Amado

Allogene Therapeutics, Inc. reported in an 8-K filed January 3, 2023 that Rafael Amado resigned as Executive Vice President of Research and Development, effective December 30, 2022. The proxy statement of Allogene Therapeutics, Inc. reports total compensation of $5,244,710 for Rafael Amado in fiscal 2022, including a base salary of $633,627. Disclosed compensation is on record for 4 fiscal years.

“On December 27, 2022, Rafael G. Amado, M.D., the Executive Vice President of Research and Development of Allogene Therapeutics, Inc. (the "Company"), notified the Company of his decision to resign, effective December 30, 2022, to pursue another opportunity.”
Allogene Therapeutics, Inc. Form 8-K, filed January 3, 2023 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2022 Allogene Therapeutics, Inc. (ALLO) $633,627 $5,244,710
2021 Allogene Therapeutics, Inc. (ALLO) $571,591 $9,714,156
2020 Allogene Therapeutics, Inc. (ALLO) $510,000 $2,663,819
2019 Allogene Therapeutics, Inc. (ALLO) $145,833 $7,452,158

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.